Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 27, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

December 1, 2025

Conditions
Amyloid Cardiomyopathy
Interventions
DRUG

Genistein

The genistein capsules are manufactured and obtained from MCS Formulas, and each capsule contains 250 mg genistein and 50 mg inulin. The genistein is certified to be 98% pure genistein by HPLC and is certified by Good Laboratory Practice (GLP). They will consume 250 mg of genistein BID (500 mg total) by mouth for the first 4 weeks before blood and stool samples are collected. Then, participants will take 500 mg of genistein BID (1000 mg total) for the next 4 weeks before collecting fasting blood and stool samples. Afterward, participants will take 750 mg of genistein BID (1500 mg total) for 4 weeks before collecting fasting blood and stool samples. Afterward, participants will have a washout for 6 weeks before returning for fasting blood and stool sample collection.

Trial Locations (1)

N6A 5A5

RECRUITING

London Regional Health Science Centre, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Greenstone Biosciences

UNKNOWN

collaborator

Stanford University

OTHER

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT06634108 - Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy | Biotech Hunter | Biotech Hunter